GlassScriptPhysician profile
Brooks Anthony Floyd
NPI 1851813877
$9,723.65
in general payments reported to CMS, 2019-2025
26 companies · $3,839 in 2025
The $3,839 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $947 · 2023: $1,880 · 2024: $2,937 · 2025: $3,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,640 · Education: $16.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,640.25 |
| Education | $16.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,786.39 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,173.61 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,108.65 | 2022-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $860.19 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $836.77 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $797.50 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $695.00 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $475.31 | 2022-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $370.61 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $235.69 | 2022-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $206.37 | 2022-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $205.02 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $154.93 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $146.28 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $120.68 | 2021-2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $106.13 | 2022-2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $90.26 | 2022-2023 | Jornay Pm |
| Neuronetics, INC. | $76.60 | 2023-2025 | Neurostar Tms Therapy System |
| Livanova USA, INC. | $52.40 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.22 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $43.68 | 2025 | Jornay Pm |
| Lilly USA, LLC | $31.22 | 2024-2025 | Zepbound, Kisunla |
| Indivior INC. | $29.60 | 2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $28.46 | 2023 | Quviviq |
| Eisai INC. | $28.37 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.